{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T01:51:31Z","timestamp":1793152291284,"version":"4.5.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T00:00:00Z","timestamp":1658188800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Diffuse large B-cell lymphoma is an aggressive and biologically heterogeneous disease. R-CHOP is the standard first line therapy and cures more than 60% of patients. Salvage high-dose chemotherapy with autologous stem cell transplant remains the standard second-line treatment for relapsed or refractory patients, and recently, three CD19 chimeric antigen receptor T cells (CART) cell products have been approved beyond 2 prior lines of systemic therapy. Nevertheless, some patients are not eligible for transplant or CARTs, or progress after these treatments. In this context, IgG-like bispecific antibodies (BsAbs) have been designed to treat B\u2010cell lymphomas. They combine two different monospecific antigen\u2010binding regions that target CD20 on B cells and engage T cells\n                    <jats:italic>via<\/jats:italic>\n                    CD3 in a 1:1 or 2:1 CD20:CD3 antigen binding fragment (Fab) format. The results of different phase 1 trials with BsAbs, including mosunetuzumab, glofitamab, epcoritamab and odeonextamab, have been recently published. They are infused intravenously or subcutaneously, and have a favorable toxicity profile, with reduced cytokine release syndrome and neurological toxicity. Moreover, these BsAbs have demonstrated very promising efficacy in B-cell lymphomas, including in aggressive lymphomas. New trials are currently ongoing to confirm BsAbs efficacy and tolerability, as well as to explore its efficacy in different lines of therapy or in combination with other drugs.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2022.909008","type":"journal-article","created":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T08:50:27Z","timestamp":1658220627000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":28,"title":["Role of Bispecific Antibodies in Relapsed\/Refractory Diffuse Large B-Cell Lymphoma in the CART Era"],"prefix":"10.3389","volume":"13","author":[{"given":"Eva","family":"Gonz\u00e1lez Barca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa011795","article-title":"CHOP Chemotherapy Plus Rituximab Compared With CHOP Alone in Elderly Patients With Diffuse Large-B-Cell Lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30935-5","article-title":"Gene Expression Profiling of Bortezomib Added to Standard Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma (REMoDL-B): An Open-Label, Randomised, Phase 3 Trial","volume":"20","author":"Davies","year":"2019","journal-title":"Lancet Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02403","article-title":"Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma","volume":"37","author":"Younes","year":"2019","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01366","article-title":"ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma","volume":"39","author":"Nowakowski","year":"2021","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.3402","article-title":"Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma","volume":"35","author":"Vitolo","year":"2017","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2115304","article-title":"Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.28.1618","article-title":"Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-11-817775","article-title":"Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results From the International SCHOLAR-1 Study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1707447","article-title":"Axicabtagene Ciloleucel CAR Tcell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)31366-0","article-title":"Lisocabtagenemaraleucel for Patients With Relapsed or Refractory Large B-Cell Lymphomas (TRANSCEND NHL 001): A Multicentreseamless Design Study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet (London England)"},{"key":"B12","first-page":"19","article-title":"Highlights in CAR T-Cell Therapy From the 62nd American Society of Hematology Annual Meeting and Exposition: Commentary","author":"Jacobson","year":"2021","journal-title":"Clin Adv Hematol Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2116596","article-title":"Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma","volume":"386","author":"Bishop","year":"2022","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-147913","article-title":"Lisocabtagene Maraleucel (Liso-Cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Versus Standard of Care (SOC) With Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2l) Treatment in Patients (Pts) With Relapsed or Refractory (R\/R) Large B-Cell Lymphoma (LBCL): Results From the Randomized Phase 3 Transform Study","volume":"138","author":"Kamdar","year":"2021","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02104","article-title":"Standardof-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006245","article-title":"Outcomes of Patients With Large B-Cell Lymphoma Progressing After Axicabtagene Ciloleucel Therapy","volume":"137","author":"Spiegel","year":"2021","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25505","article-title":"Outcomes of Patients With Large B-Cell Lymphomas and Progressive Disease Following CD19-Specifc CAR T-Cell Therapy","volume":"94","author":"Chow","year":"2019","journal-title":"Am J Hematol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007512","article-title":"Final Results of a Phase 1 Study of Loncastuximab Tesirine in Relapsed\/Refractory B-Cell Non-Hodgkin Lymphoma","volume":"137","author":"Hamadani","year":"2021","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(20)30225-4","article-title":"Tafasitamab Plus Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (L-MIND): A Multicentre, Prospective, Single-Arm, Phase 2 Study","volume":"21","author":"Salles","year":"2020","journal-title":"Lancet Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.00172","article-title":"Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30120-4","article-title":"Selinexor in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (SADAL): A Singlearm, Multinational, Multicentre, Open-Label, Phase 2 Trial","volume":"7","author":"Kalakonda","year":"2020","journal-title":"Lancet Haematol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.00931","article-title":"Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study","volume":"40","author":"Budde","year":"2021","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-135818","article-title":"Subcutaneous Mosunetuzumab in Relapsed or Refractory B-Cell Lymphoma: Promising Safety and Encouraging Efficacy in Dose Escalation Cohorts","volume":"136","author":"Matasar","year":"2020","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136255","article-title":"Single-Agent Mosunetuzumab Is a Promising Safe and Efficacious Chemotherapy-Free Regimen for Elderly\/Unfit Patients With Previously Untreated Diffuse Large B-Cell Lymphoma","volume":"136","author":"Olszewski","year":"2020","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136295","article-title":"Mosunetuzumab, a Novel CD20\/CD3 Bispecific Antibody, in Combination With CHOP Confers High Response Rates in Patients With Diffuse Large B Cell Lymphoma","volume":"136","author":"Phillips","year":"2020","journal-title":"Blood"},{"key":"B27","first-page":"533","article-title":"Mosunetuzumab Plus Polatuzumab Vedotin Has Promising Efficacy and a Favorable Safety Profile in Patients With Relapsed\/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma: Updated Results From a Phase Ib\/II Study","volume":"138","author":"Budde","year":"2021","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1182\/blood-2021-147937","article-title":"Subcutaneous (SC) Administration of Mosunetuzumab With Cycle 1 Step-Up Dosing Is Tolerable and Active in Patients With Relapsed\/Refractory B-Cell Non-Hodgkin Lymphomas (R\/R B-NHL): Initial Results From a Phase I\/II Study","volume":"138","author":"Bartlett","year":"2021","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.03175","article-title":"Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell\u2013Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial","volume":"39","author":"Hutchings","year":"2021","journal-title":"J Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)00889-8","article-title":"Dose Escalation of Subcutaneous Epcoritamab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: An Open-Label, Phase 1\/2 Study","volume":"398","author":"Hutchings","year":"2021","journal-title":"Lancet"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1182\/blood-2021-146569","article-title":"Subcutaneous Epcoritamab in Combination With R-CHOP in Patients With Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma: Preliminary Results From a Phase 1\/2 Trial","volume":"138","author":"Belada","year":"2021","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136659","article-title":"Odronextamab (REGN1979), a Human CD20 X CD3 Bispecific Antibody, Induces Durable, Complete Responses in Patients With Highly Refractory B-Cell Non-Hodgkin Lymphoma, Including Patients Refractory to CAR T Therapy","volume":"136","author":"Bannerji","year":"2020","journal-title":"Blood"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.909008\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T08:50:31Z","timestamp":1658220631000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.909008\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,19]]},"references-count":32,"alternative-id":["10.3389\/fimmu.2022.909008"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.909008","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,19]]},"article-number":"909008"}}